tbuckley/cabot-search huggingface dataset:
ATIM-32. PHASE IIA CLINICAL TRIAL EVALUATING DENDRITIC CELL VACCINE FOR THE TREATMENT OF LOW-GRADE GLIOMAS
Authors: Diana Moughon, Richard Everson, Sylvia Odesa, Horacio Soto, Emma Billingslea-Yoon, Shaina Sedighim, Joey Orpilla, Jeffrey Lin, Robert Prins, Linda Liau
Journal: Neuro-Oncology (2016)

We conducted an exploratory phase IIa clinical trial to evaluate the safety and efficacy of autologous tumor lysate-pulsed dendritic cell vaccine therapy in patients with low grade gliomas. Five patients, three with newly-diagnosed and two with recurrent grade II gliomas, enrolled and each received at least one injection of the vaccine. The treatment was well-tolerated with only mild side effects such as headache, myalgia and fatigue. There were no grade 3 or 4 adverse events. Interestingly, the patient with the longest progression-free survival, almost 43 months, was 85 years of age at the time of surgery with a diagnosis of IDH1-wildtype 1p/19q-intact astrocytoma, the most aggressive pathology in the trial. The patient whose tumor has not yet progressed, with a TTP >27 months to date, was one of the recurrent tumors at the time of vaccine. Antibody responses to IDH1 R132H mutation, a known neoantigen present in 4/5 tumors, were measured and found to be present in all four patients with IDH mutant tumors by ELISA. We analyzed pre- and post-vaccine tumor specimens of two patients and found significant increases of CD8+ PD-1+ tumor-infiltrating lymphocytes (TILs), but no significant increase of PD-L1 expression in the tumor cells themselves. There was no significant difference in time to progression for the patients in this clinical trial compared control patients who were matched for tumor grade, type, recurrence number, IDH1 status and 1p/19q status. Such findings indicate that further research is warranted to understand why certain low-grade tumors respond better to the vaccine than others. There was also evidence of a PD-1+ cytotoxic T-cell infiltration induced by the vaccine that may benefit from combined PD-1 blockade therapy.
Role of p21 Activated Kinase and Specific Guanine Exchange Factors of Rac Gtpases in Oncogenic KIT Induced Systemic Mastocytosis and Acute Myeloid Leukemia
Authors: Holly Martin, Peilin Ma, Anindya Chatterjee, Baskar Ramdas, Emily Sims, Cornelis Vlaar, Suraganie Dharmawardhane, Reuben Kapur
Journal: Blood (2012)
The Counselling by CNT for the Exportation of Umbilical Cord Stem Cells for Autologous Use
Authors: Francesca D’Alessandro, Antonella Tancredi, Letizia Lombardini, Silvia Pisanu, Elisa Faraci, Giorgia Santangelo, Erica Villa, Sante Venettoni, Alessandro Nanni Costa
Journal: Blood (2008)
Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12∼23 Amplification
Authors: Jeffrey Sawyer, Erming Tian, Christoph Heuck, Qing Zhang, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Sarah Waheed, Saad Z Usmani, Frits van Rhee, Bart Barlogie
Journal: Blood (2012)
Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center
Authors: Justin M Watts, Ashwin Kishtagari, Sean Devlin, Eytan M Stein, Jae H Park, Mario E Lacouture, Martin Tallman
Journal: Blood (2013)
Lycorine Modulates the Expression of p21 Via a p53-Independent Pathway in HL-60 Cells
Authors: Jing Liu, Shu-Ling Wang, Lin Fang, Mao Ye, Zhi-Wei Sun, Lv Li, Zi Wang, Hui-Wen Yan, Sai-Qun Luo, Hui-Yong Chen, Xiuli An, Wei-Xin Hu
Journal: Blood (2011)
Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.
Authors: Patrizia Tosi, Elena Zamagni, Paola Tacchetti, Michela Ceccolini, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Alessandro Petrucci, Michele Baccarani, Michele Cavo
Journal: Blood (2009)
A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
Authors: Mary E. Strek, Justin M. Oldham, Ayodeji Adegunsoye, Rekha Vij
Journal: European Respiratory Journal (2016)

We appreciate the letter of correspondence by A.S. Jee and colleagues highlighting the need to standardise the rheumatologic classification criteria utilised in the diagnosis of a defined connective tissue disease (CTD) when evaluating patients with interstitial lung disease (ILD) for autoimmune features and CTD. This was prompted by our recent publication in the European Respiratory Journal [1]. A.S. Jee and colleagues note that the interstitial pneumonia with autoimmune features (IPAF) cohort in our study contained only one subject with an anti-tRNA synthetase antibody and speculate that patients at our centre with positive antisynthetase antibodies and ILD were diagnosed with an antisynthetase syndrome rather than IPAF [2]. This observation prompted A.S. Jee and colleagues to highlight the numerous criteria that exist for the diagnosis of the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and antisynthetase syndrome and propose that these entities be defined uniformly in the evaluation of patients with ILD. This approach would more precisely distinguish IPAF patients from those with CTD-ILD with potential improvement in the accuracy and prognostic ability of the IPAF criteria. IPAF criteria need to be implemented in a standard fashion across centres for accurate validation <http://ow.ly/W7Fz304BKq0>
An Unexpected Role for the Complement C5b-C9 Membrane Attack Complex (MAC) In Trafficking of Hematopoietic Stem/Progenitor Cells - a Novel Unexpected Link Between Innate Immunity and Hematopoiesis
Authors: Chihwa Kim, Wu Wan, Rui Liu, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2010)
Evaluation of Inherited Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia.
Authors: Valerie Li Thiao Te, Remi Favier, Jeanne-Yvonne Borg, Estelle Cadet, Jacqueline Reynaud, Julie Micheli, Petronela Rachieru, Claire Berger, Anne Auvrignon, Pascale Schneider, Guy Leverger, Brigitte Pautard Muchemble
Journal: Blood (2007)
Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.
Authors: Jean-Michel Cayuela, Philippe Rousselot, Franck Nicolini, Daniel Espinouse, Christophe Ollagnier, M.H. Bui-Thi, Kaddour Chabane, E. Raffoux, Isabelle Tigaud, Jean-Pierre Magaud, Sandrine Hayette
Journal: Blood (2005)
Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.
Authors: O. Cornely, J. Maertens, D. Winston, J. Perfect, D. Helfgott, A. Ullmann, J. Holowiecki, D. Stockelberg, Y.-T. Goh, M. Petrini, T. Walsh, J. Gogate, C. Hardalo, D. Angulo-Gonzalez
Journal: Blood (2005)
Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia
Authors: Elizabeth J Murphy, Donna Neuberg, Kanti R. Rai, Laura Rassenti, Claire Emson, Kelvin Li, Neil E. Kay, William G. Wierda, Gregory M Hayes, Jennifer R. Brown, John C. Byrd, Coline McConnel, Jacqueline C. Barrientos, Robert Allyn Redd, Scott Turner, Robert Busch, Andrew Greaves, Marc Hellerstein, Nicholas Chiorazzi, Thomas J. Kipps
Journal: Blood (2014)
Margaret McCartney: Evidence in a post-truth world
Authors: Margaret McCartney
Journal: BMJ (2016)

Is the internet making us more stupid? The outcome of the US presidential election will be analysed as a caustic case study long after we’re all dead, but the internet must take at least some of the blame. We’re in a post-fact, post-truth, we’ve-had-enough-of-experts era.

I remember realising that knowledge no longer meant a date with Index Medicus (young people: this was a multi-volume, paper—paper!—bibliography that started the hours-long search for research, during library opening hours only). The internet has driven through multiple barriers and has made resources such as Testing Treatments, Understanding Uncertainty, or open …
Rituximab-CHOP Versus CHOP Alone in Patients with Diffuse Large B Cell Lymphoma.
Authors: Mustafa Cetiner, Taflan Salepci, Elif Birtas Atesoglu, Mahmut Gumus, Aslihan Guven, Levent Undar, Tulin Firatli Tuglular, Mahmut Bayik
Journal: Blood (2006)
Full Dose Treosulfan Based Reduced Toxicity Conditioning Regimen in Allogeneic Stem Cell Transplantation: Results in 123 Patients.
Authors: Alessandro Lorusso, Roberto Crocchiolo, Carlo Messina, Fabio Giglio, Alessandra Forcina, Sara Mastaglio, Maria Teresa Lupo Stanghellini, Andrea Assanelli, Salvatore Gattillo, Katharina Fleischhauer, Magda Marcatti, Consuelo Corti, Massimo Bernardi, Chiara Bonini, Fabio Ciceri, Jacopo Peccatori
Journal: Blood (2012)
Rasburicase Improves Renal Function and Uric Acid Nephropathy in Patients Developing Acute Renal Failure after Conditioning for Hematopoetic Stem Cell Transplant (HSCT).
Authors: Donovan Strader, Michael S. Oholendt, Uday Popat, George Carrum, Helen E. Heslop
Journal: Blood (2004)
Response to Open Peer Commentaries on “Diagnosis By Television Documentary: Professional Responsibilities in Informal Encounters”
Authors: Alistair Wardrope, Markus Reuber
Journal: The American Journal of Bioethics (2016)

In presenting the situation of a health professional witnessing an instance of misdiagnosis and mistreatment in a television documentary, we hoped to stimulate discussion of the professional responsibilities of health workers in informal encounters in a rapidly changing environment comprising print, television, and more recently social media platforms. The commentaries on our article do not disappoint in this respect, providing insightful and sometimes challenging reactions to the position we outlined in response to our original case. In our reply here, we choose to focus on two themes running through all of the commentaries: (1) the distinction between axiological and deontic perspectives invoked by Salloch, and the open-endedness of the former that we see as crucial in addressing the constantly changing media landscape through which health workers may confront medical need; and (2) the role of institutional, structural, and social factors in constraining or enabling virtuous professional practice—suggesting perhaps a further need for health workers to take action directly against structural injustices that prevent them from fulfilling their professional responsibilities.
One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.
Authors: Domenico Russo, Giovanni Martinelli, Michele Malagola, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani
Journal: Blood (2010)
A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach
Authors: Deepak Kumar, Manoj Kumar Kashyap, Ide Spaanderman, Reymundo Villa, Laura Rassenti, James La Clair, Michael D. Burkat, Thomas J. Kipps, Januario E. Castro
Journal: Blood (2013)
Are Back-Up Bone Marrow Harvests of Value in Unrelated Donor Allogeneic Transplants?.
Authors: Christy Stotler, Edward Copelan, Ronald Sobecks, Lisa Rybicki, Robert Dean, Steven Andresen, Brad Pohlman, John William Sweetenham, Stacey Brown, Matt Kalaycio, Julie Curtis, Karen Sands, Mary Serafin, Jennifer Kosar, Brian Bolwell
Journal: Blood (2007)
Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition
Authors: Meibao Feng, Jieqiong Feng, Wuzhen Chen, Wubin Wang, Xuesong Wu, Jing Zhang, Fangying Xu, Maode Lai
Journal: Molecular Cancer (2016)

Lipocalin2 (LCN2) is a secretory protein that is aberrantly expressed in several types of cancer and has been involved in metastatic progression. However, neither mechanisms nor the role that LCN2 plays in the metastasis of colorectal cancer are clear.LCN2 expression in colorectal cancer was detected by immunohistochemistry in 400 tissue specimens and Kaplan-Meier survival analysis was performed. In vitro, real-time PCR, western blot, colony formation assay, immunofluorescence assay, wound healing assay, migration and invasion experiment were performed to investigate the effects of LCN2 in epithelial mesenchymal transition (EMT), migration and invasion, respectively. In vivo mouse xenograft and metastasis models were utilized to determine tumorigenicity and metastasis ability, and immunohistochemistry, real-time PCR, western blot were used to evaluate the related protein expression. Luciferase reporter assay was used to explore the role of LCN2 on NF-ĸB promoter.LCN2 was highly expressed in 66.5% of the specimens, and significantly correlated with positive E-cadherin in the membrane and negative nuclear β-catenin. Higher expression of LCN2 together with negative NF-κB expression was negatively related to nuclear accumulation of snail and predicted favorable prognosis. LCN2 blocked cell proliferation, migration and invasion in vitro and in vivo, and inhibited translocation of NF-κB into nucleus. NF-κB could reverse the effect of LCN2 on EMT and promote snail expression. Rescued snail expression had similar effect without influencing NF-κB activity.LCN2 may be an important negative regulator in EMT, invasion and metastasis of CRC via acting as upstream of NF-κB/snail signaling pathway. Thereby combinative manipulation of LCN2 and NF-κB/snail pathway may represent a novel and promising therapeutic approach for the patients with CRC.
Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Authors: Danielle M. Brander, Sallie D. Allgood, David A. Rizzieri, Tiffany Stewart, J. Brice Weinberg, Mark C Lanasa
Journal: Blood (2014)
In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.
Authors: Lara Rossi, Rossella Manfredini, Francesco Bertolini, Davide Ferrari, Miriam Fogli, Roberta Zini, Simona Salati, Sergio Ferrari, Francesco Di Virgilio, Michele Baccarani, Roberto M. Lemoli
Journal: Blood (2005)
Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.
Authors: Michael Schleuning, Christoph Schmid, Christian Koenecke, Bernd Hertenstein, Herrad Baurmann, Rainer Schwerdtfeger, Hans-Jochem Kolb
Journal: Blood (2008)
Initial Features and Outcome Are Similar in Patients with Lymphoplasmacytic Lymphoma Regardless They Meet or Not Criteria of Waldenström Macroglobulinemia,
Authors: Eva Giné, Jordina Rovira, Alejandra Martinez-Trillos, Neus Villamor, Antonio Martinez, Gonzalo Gutierrez-Garcia, Luis Colomo, Julio Delgado, Tycho Stephan Baumann, Elias Campo, María Rozman, Armando Lopez-Guillermo
Journal: Blood (2011)
The Therapeutic Effect of Lenalidomide Is Enhanced After Allogeneic Stem Cell Transplantation: Results of a Case-Control Study
Authors: Vittorio Montefusco, Francesco Spina, Elena Zamagni, Giorgia Saporiti, Francesca Patriarca, Monica Galli, Claudia Crippa, Lucia Farina, Anna Maria Cafro, Paolo Corradini
Journal: Blood (2011)
MDS and AML Are Closely Related Diseases: Gene Expression Patterns Reveal Clear Similarities with Respect to Karyotypes and Are Less Related to the Bone Marrow Blast Percentages.
Authors: Torsten Haferlach, Wolfgang Kern, Alexander Kohlmann, Martin Dugas, Sylvia Merk, Wolfgang Hiddemann, Susanne Schnittger, Claudia Schoch
Journal: Blood (2004)
Abstract 17689: Omega-3 Fatty Acid Supplementation Reduces Inflammation and Improves Physical Function in Patient With Coronary Artery Disease
Authors: Abdulhamied Alfaddagh, Francine K Welty
Journal: Circulation (2015)

Introduction: Poor physical function impairs fitness and is associated with worse cardiovascular outcomes and all-cause mortality. Arthritis and joint dysfunction limit physical function in coronary artery disease (CAD) patients. Hypothesis: Omega-3 fatty acids (FA) improve physical function in CAD patients through reducing inflammation. Methods: We randomized 249 subjects with stable CAD to 3.6 of omega-3 FA (1.86 g of eicosapentaenoic acid + 1.5 g of docosahexaenoic acid) per day or no omega-3 (control) for one year. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used to evaluate pain, stiffness and physical function at baseline and one year follow-up. Inflammation was assessed by total white blood cell (WBC) count and its subsets as well as urine microalbumin-creatinine ratio (MCR). Results: Mean age was 63.0 ± 7.58 years; 17% were women. Controls had worsening stiffness (% Δ = 8.4%; p = 0.036) at 1 year follow-up while those on omega-3 FA had no change (% Δ = 0.4%, p = 0.886 - see Table)(a lower percent change indicates better functioning). Compared to controls, those on omega-3 FA had better physical function (% Δ = 8.5% vs. -2.8%, p = 0.011), and total WOMAC scores (% Δ = 7.8% vs. -2.5%, p = 0.011) and a significant decrease in WBC (% Δ = -3.5 vs. -9.4%; p=0.009) and neutrophils (% Δ = -3.5% vs. -11.6%; p=0.005) at one year follow-up. MCR significantly worsened only in the control group (% Δ = 53.3%, p = 0.037) at one year follow-up (p-value for control vs. omega-3 FAs groups = 0.026). Monocytes were decreased in the omega-3 FAs group at one year compared to baseline (% Δ = -11.1%, p &lt; 0.001) and directly correlated with physical function and total scores (p = 0.033 and p = 0.024, respectively). Conclusions: Omega-3 FAs attenuate worsening of physical function over a one year period in CAD patients possibly mediated through an anti-inflammatory effect. Therefore, omega-3 FA may benefit CAD patients by improving their physical function.
Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.
Authors: Omer N. Koc, Charles Redfern, Peter H. Wiernik, Fred Rosenfelt, Jane N. Winter, Troy H. Guthrie, Lawrence Kaplan, Peter Holman, John Densmore, John Hainsworth, Thomas S. Lin, Rene A. Castillo, Nalini Janakiraman, Richard G. Ghalie
Journal: Blood (2007)
Life after Fludarabine, Cyclophosphamide, &amp; Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR.
Authors: Constantine S. Tam, William G. Wierda, Susan O’Brien, Susan Lerner, Issa F Khouri, Hagop M. Kantarjian, Michael J Keating
Journal: Blood (2008)
Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.
Authors: Brad Kahl, Nancy L. Bartlett, John P. Leonard, Kristen Ganjoo, Michael E. Williams, Myron S. Czuczman, K. Sue Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson
Journal: Blood (2007)
Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease
Authors: Isabel N. Schellinger, Nada Cordasic, Julian Panesar, Björn Buchholz, Johannes Jacobi, Andrea Hartner, Bernd Klanke, Joanna Jakubiczka-Smorag, Nicolai Burzlaff, Eva Heinze, Christina Warnecke, Uwe Raaz, Carsten Willam, Philip S. Tsao, Kai-Uwe Eckardt, Kerstin Amann, Karl F. Hilgers
Journal: Kidney International (2016)
Virus Reactivation Profile as Assessed by PCR and Serology Pattern Following First-Line Alemtuzumab (Anti-CD52 Monoclonal Antibody, Campath®) Therapy in Patients with B-CLL.
Authors: C. Karlsson, H. Dahl, A. Linde, J. Lundin, M. Björkholm, H. Mellstedt, A. Osterborg
Journal: Blood (2004)
Gun Violence and Firearm Safety in Medical School Curricula
Authors: Arianna F. Yanes
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
NPM-ALK Promotes Cell Cycle Progression through Activation of JNK and c-Jun in Anaplastic Large Cell Lymphoma.
Authors: Vasiliki Leventaki, Elias Drakos, Megan Lim, Kojo S. Elenitoba-Johnson, Francois-Xavier Claret, L. Jeffrey Medeiros, George Z. Rassidakis
Journal: Blood (2006)
Medical Treatment of Aortic Stenosis
Authors: Guillaume Marquis-Gravel, Björn Redfors, Martin B. Leon, Philippe Généreux
Journal: Circulation (2016)

Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis. The only treatment shown to improve survival is aortic valve replacement; however, before symptoms occur, aortic stenosis is preceded by a silent, latent phase characterized by a slow progression at the molecular, cellular, and tissue levels. In theory, specific medical therapy should halt aortic stenosis progression, reduce its hemodynamic repercussions on left ventricular function and remodeling, and improve clinical outcomes. In the present report, we performed a systematic review of studies focusing on the medical treatment of patients with aortic stenosis. Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have been the main drug classes studied in this setting and are reviewed in depth. A critical appraisal of the preclinical and clinical evidence is provided, and future research avenues are presented.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM)
Authors: Xavier Leleu, Steven Legouill, Chanaz Louni, Karlin Lionel, Anne Banos, Bertrand Arnulf, Marie Odile Petillon, Olivier Tournilhac, Pierre Morel, Veronique Leblond
Journal: Blood (2014)
Tobacco companies consider next move after failing to overturn plain packaging ruling
Authors: Clare Dyer
Journal: BMJ (2016)

Tobacco companies challenging the United Kingdom’s plain packaging law are considering taking their case to the Supreme Court after a decisive loss at the Court of Appeal.1

On 30 November three senior judges upheld a ruling by the High Court last May that the UK government was legally entitled to introduce regulations intended to severely limit the potential of packaging to entice new …